Filing Flows › Comparisons › ALGS vs ELUT
Aligos Therapeutics vs Elutia: ALGS and ELUT compared
Aligos Therapeutics is the larger company: $2.8M of revenue in its latest quarter (Q3 2026) against $2.4M for Elutia (Q2 2026). Aligos Therapeutics is growing faster (+282% against -12% a year earlier). Elutia is more profitable, with an operating margin of -327.9% against -773.5%.
Where the money goes: ALGS and ELUT
Aligos Therapeutics (ALGS) · Q3 2026
Aligos Therapeutics, Q3 2026: revenue $2.8M (+282% year over year), operating margin -773.5%, net loss $21.9M, operating cash flow $1.5M. The chart follows the revenue to costs, profit and cash.
Elutia (ELUT) · Q2 2026
Elutia, Q2 2026: revenue $2.4M (-12% year over year), operating margin -327.9%, net loss $7.6M, operating cash flow −$8.5M. The chart follows the revenue to costs, profit and cash.
| Aligos Therapeutics (ALGS) | Elutia (ELUT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $2.8M | $2.4M |
| Revenue growth, Y/Y | +282% | -12% |
| Operating margin | -773.5% | -327.9% |
| Net earnings | −$21.9M | −$7.6M |
| Net margin | -772.4% | -315.0% |
| Operating cash flow | $1.5M | −$8.5M |
| Market value | $55.7M | — |
| Analysts’ mean target | $52.38 | — |
Questions
Which is bigger, Aligos Therapeutics or Elutia?
Aligos Therapeutics is the larger company: $2.8M of revenue in its latest quarter (Q3 2026) against $2.4M for Elutia (Q2 2026).
Is Aligos Therapeutics or Elutia growing faster?
Aligos Therapeutics is growing faster (+282% against -12% a year earlier).
Which is more profitable, Aligos Therapeutics or Elutia?
Elutia is more profitable, with an operating margin of -327.9% against -773.5%.
More: Aligos Therapeutics earnings · how Aligos Therapeutics makes money · Elutia earnings · how Elutia makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.